Artikel
SARS: A case study for biodefense
Suche in Medline nach
Autoren
Veröffentlicht: | 26. Mai 2004 |
---|
Gliederung
Text
Lessons learned from the global SARS experience should shape strategies for responding to future epidemics, whether an epidemic is natural or man-made. While the bioresearch response to SARS has been swift and effective, it has highlighted important differences between the normal pace and process of scientific research, and what is required in a time of crisis. These differences should be examined and discussed, to establish 'ground rules' and policies designed to ease the bioresearch response in future epidemics. From an analysis of SARS bioresearch events, as well as interviews, aspects that need to be considered include: mechanisms to garner financial support for researching an emerging crisis, rules for scientific collaboration including intellectual property concerns, ensuring that scientists are professionally rewarded for their participation in a crisis response, communicating scientific information when it is time-sensitive (peer-reviewed journals vs. CNN), and biosafety standards.
While there are many aspects of the SARS experience that are analogous to a hypothesized bioweapons attack (a 'new' virus, high mortality, global impact, and the destruction of economy and livelihood), there are several potential differences: in a bioweapons attack, there is the possibility of several outbreaks at once, with the potential involvement of different players, officials, and experts. The challenges for a bioresearch response in this scenario will be presented and discussed.